What the Future Holds for NASH: An Augmented Reality Look into Disease Stating and Targeted Therapies

CMEO Medical Meeting

Symposium Date: Sunday, November 10, 2019
on November 11, 2019 at the Marriott Copley Place, Boston, MA

This activity offers CE credit for:

  1. Physicians (CME)
  2. Nurses (CNE)
  3. Pharmacists (ACPE)
  4. ABIM (MOC)
  5. Other


Credit Expiration Date: Tuesday, November 10, 2020
Note: Credit Is No Longer Available

Faculty


Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD 
Chairman, Department of Medicine
Professor Medicine
Inova Fairfax Hospital
Falls Church, VA

Rohit Loomba, MD, MHSc Rohit Loomba, MD, MHSc 
Director, NAFLD Research Center Director of Hepatology Professor of Medicine
Vice Chief, Division of Gastroenterology
University of California, San Diego
San Diego, CA

Mazen Noureddin, MD, MHSc Mazen Noureddin, MD, MHSc 
Director, Fatty Liver Program
Division of Digestive & Liver Diseases
Comprehensive Transplant Center
Cedars Sinai Medical Center
Los Angeles, CA

Statement of Need

Given the rising prevalence of non-alcoholic fatty liver disease (NAFLD) and the societal and economic burden of its aggressive subtype, non-alcoholic steatohepatitis (NASH), it is important that hepatologists and gastroenterologists are equipped with the latest tools to diagnose NASH. While there are currently no approved therapies for the treatment of NASH, several targeted therapies are being investigated in clinical trials, with high probability of being approved in the near future. Hence, it is imperative that hepatologists and gastroenterologists have up to date knowledge regarding the latest clinical data on NASH therapies.

This CME Outfitters symposium will feature expert faculty integrating augmented reality (AR) to discuss pathways, therapeutic targets, and disease progression providing the learners with the best visual experience to enable them to integrate the latest tools for diagnosis and management of patients with NASH.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Describe the role of immune, inflammatory, and metabolic pathways in the pathogenesis of NASH.
  • Select appropriate non-invasive and invasive modalities for the identification of advanced fibrosis in patients with NAFLD.
  • Evaluate the efficacy of emerging therapies for improving fibrosis in patients with NASH.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Describe the role of immune, inflammatory, and metabolic pathways in the pathogenesis of NASH.
  • Determine appropriate non-invasive and invasive modalities for the identification of advanced fibrosis in patients with NAFLD.
  • Evaluate the efficacy of emerging therapies for improving fibrosis in patients with NASH.

Financial Support

Supported by an educational grant from Intercept Pharmaceuticals.

Target Audience

Hepatologists, gastroenterologists, endocrinologists, diabetologists, primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists.

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15) CEUs). Universal Activity Number:
Live: 0376-0000-19-038-L01-P

Type: knowledge-based

ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Learning Formats
Live activity

Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM from organizations accredited by the Accreditation Council for Continuing Medical Education.

MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Noureddin reports that he receives research support from Allergan; Bristol-Myers Squibb Company; Conatus Pharmaceuticals Inc.; Enanta Pharmaceuticals, Inc.; Galectin Therapeutics Inc.; Galmed Pharmaceuticals; GENFIT; Gilead Sciences, Inc.; Novartis; and Shire and Zydus Pharmaceuticals, Inc. He is on the advisory board or speakers bureau for Abbott; Allergan; Blade Therapeutics; EchosensTM North America; Gilead Sciences, Inc.; Intercept Pharmaceuticals, Inc.; Novartis; OWL; Pfizer Inc.; and Simply Speaking, Inc. He is a stock shareholder (directly purchased) of Viking Therapeutics and Ananetos.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty has been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

MM-095-111019-60